Arbutus Biopharma (ABUS) Misses Q2 EPS by 1c

Arbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of ($0.23), $0.01 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $2.33 million versus the consensus estimate of $2.12 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Societe Generale SA (GLE:FP) (SCGLY) PT Raised to EUR83 at JPMorgan
• Union Pacific (UNP) Reiterated at Market Outperform by Citizens - Most Attractive in Rail Group